While inhibiting MerTK in other cancers (e.g., melanoma, pancreatic, colon cancers, and hepatocellular carcinoma) suppresses pro-tumor immune cells and cytokines (40–42), in TNBC MerTK overexpression uniquely enhances anti-tumor immune infiltration in murine 4T1 tumors (Figures 1, 4). Here, MERTK is linked to neoplasm.